Gender, underutilization of cardiac resynchronization therapy, and prognostic impact of QRS prolongation and left bundle branch block in heart failure

Europace

Volumn 17, Issue 3, 2015, Pages 424-431

  Linde, Cecilia ^a,b   Ståhlberg, Marcus ^a,b   Benson, Lina ^c   Braunschweig, Frieder ^a,b   Edner, Magnus ^a,b   Dahlström, Ulf ^d   Alehagen, Urban ^d   Lund, Lars H ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c STOCKHOLM SÖDER HOSPITAL   (Sweden)

^d LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Cardiac resynchronization therapy; Epidemiology; Gender; Heart failure; Left bundle branch block; QRS width

Indexed keywords

AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOLOGIST; CONGESTIVE CARDIOMYOPATHY; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART VENTRICLE CONDUCTION; HUMAN; HYPERTENSION; INTRAVENTRICULAR CONDUCTION DELAY; ISCHEMIC HEART DISEASE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QRS COMPLEX; QRS PROLONGATION; REVASCULARIZATION; SEX DIFFERENCE; SURVIVAL; ARRHYTHMIAS, CARDIAC; BUNDLE-BRANCH BLOCK; COMPLICATION; CONGENITAL MALFORMATION; HEART MUSCLE CONDUCTION SYSTEM; HEART STROKE VOLUME; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRACTICE GUIDELINE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REGISTER; SWEDEN; UTILIZATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ARRHYTHMIAS, CARDIAC; BUNDLE-BRANCH BLOCK; CARDIAC RESYNCHRONIZATION THERAPY; FEMALE; GUIDELINE ADHERENCE; HEART CONDUCTION SYSTEM; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; SEX FACTORS; STROKE VOLUME; SWEDEN;

EID: 84924429413     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euu205     Document Type: Article

References (31)

1. Cazeau S, Leclercq C, Lavergne T,Walker S, Varma C, Linde Cet al. Multisite Stimulation in Cardiomyopathies (MUSTIC) Study Investigators. Effects ofmultisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001;344:873-80.
2. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L et al. Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization therapy on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539-49.
3. Linde C, Abraham WT, Gold MR, St John Sutton M, Ghio S, Daubert C. REVERSE (Resynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) Study Group. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 2008;52:1834-43.
4. Daubert C, Gold MR, Abraham WT, Ghio S, Hassager C, Goode G et al. REVERSE Study Group. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction. Insight from the European cohort of the REVERSE trial. J Am Coll Cardiol 2009;54:1837-46.
5. Moss AJ, Hall WJ, Cannom DS, Klein H, BrownMW, Daubert JP et al. MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heartfailure events. N Engl J Med 2009;361:1329-38.
6. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S et al. Resynchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 2010;363:2385-95.
7. van Veldhuisen DJ, Maas AH, Priori SG, Stolt P, van Gelder IC, Dickstein K et al. Implementation of device therapy (cardiac resynchronization therapy and implantable cardioverter defibrillator) for patients with heart failure in Europe: changes from 2004 to 2008. Eur J Heart Fail 2009;12:1143-51.
8. ZarebaW, Klein H, Cygankiewicz I, Hall WJ, McNitt S, Brown M et al. MADIT-CRT investigators, effectiveness of cardiac resynchronization therapy by QRS morphology in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT). Circulation 2011;123:1061-72.
9. Gold M, Thebault C, Linde C, Abraham WT, Gerritse B, Ghio S et al. The Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the Resynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) Study. Circulation 2012;126:822-9.
10. Stevenson WG, Hernandez AF, Carson PE, Fang CJ, Katz SD, Spertus JA et al. From the Heart Failure Society of America Guideline Committee. Indications for cardiac resynchronization therapy: 2011 update from the Heart Failure Society of America guideline committee. J Card Fail 2012;18:94-106.
11. Tracy CM, Epstein AE, Darbar D, DiMarco JP, Dunbar SB, Estes NA 3rd et al. 2012 ACCF/AHA/HRS Focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. Heart Rhythm 2012;9:1737-53.
12. McMurray JJ,Adamopoulos S, Anker SD, Auricchio A, BohmM, DicksteinKet al. ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803-69.
13. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA).Authors/task force members. Europace 2013; 15:1070-118.
14. Zabarovskaja S, Gadler F, Stahlberg M, Hornsten J, Braunschweig F, Linde C et al. Women have better long-term prognosis than men after cardiac resynchronization therapy implantation. Europace 2012;14:1148-55.
15. Arshad A, Moss AJ, Foster E, Padeletti L, Golderberg I, Greenberg H et al. Cardiac Resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy) trial. J Am Coll Cardiol 2011;57:813-20.
16. Bogale N, Priori S, Cleland JFG, Brugada J, Linde C, Auricchio A et al. The European CRT survey: 1 year follow up results. Eur Heart J 2012;14:61-73. 88.
17. Dickstein K, Bogale N, Priori S, Auricchio A, Cleland JG, Gitt A et al. on behalf of the Scientific Committee and National Coordinators. European cardiac resynchronisation therapy (CRT) survey. Eur Heart J 2009;30:2450-60.
18. Yarnoz MJ, Curtis AB. Sex-based differences in cardiac resynchronization therapy and implantable cardioverter defibrillator therapies. Effectiveness and use. Cardiol Rev 2006;6:292-8.
19. Lund LH, Jurga J, Edner M, Benson L, Dahlstrom U, Linde C et al. Prevalence, correlates and prognostic significance of QRS prolongation in heart failure with reduced and preserved ejection fraction. Eur Heart J 2013;34:529-39.
20. JonssonA , Edner M, Alehagen U, DahlstromU. Heart failure registry: a valuable tool for improving the management of patients with heart failure. Eur J Heart Fail 2010;12: 25-31.
21. Lund LH, Benson L, Dahlstrom U, Edner M. Association between use of rennin- angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA 2012;308:2108-21117.
22. Therneau T, Grambsch P. Modeling survival data: extending the Cox model. New York: Springer-Verlag; 2000.
23. Hubinette C, Lund LH, Gadler F, Stahlberg M. Awareness of indications for device therapy among a broad range of physicians. Results of a survey. Europace 2014;16: 1580-6.
24. Curtis LH, Al-Khatib SM, Shea AM, Hammill BG, Hernandez AF, Schulman KA. Sex differences in the use of implantable cardioverter defibrillators for primary and secondary prevention of sudden cardiac death. JAMA 2007;298: 1517-24.
25. StraussDG, Selvester RH,Wagner GS. Defining left bundle branch block in the era of cardiac resynchronization therapy. Am J Cardiol 2011;107:927-34.
26. MacFarlane P, Oosterom AV, Pahlm O, Kligfield P, Janse M, Camm J. Appendix 1 6 normal limits. Comprehensive electrocardiology. 2nd ed. London: Springer-Verlag London Limited, 2011;2057-125.
27. Baldasseroni S, Opasich C, Gorini M, Lucci D, Marchionni N, Marini M et al. Italian Network on Congestive heart Failure Investigators. Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. Am Heart J 2002;143:398-405.
28. Bilchick KC, Kamath S, Dimarco JP, Stukenborg GJ. Bundle-branch block morphology and other predictors of outcome after cardiac resynchronization therapy in medicare patients. Circulation 2010;122:2022-30.
29. Loring Z, Canos A, Selzman K, HerzND,Silverman H, MacCurdyTE et al. Left bundle branch block predicts better survival in women than men receiving cardiac resynchronization therapy-long term follow-up of about 145 000 patients. J Am Coll Cardiol Heart Fail 2013;1:237-44.
30. Auricchio A, Fantoni C, Regoli F, Carbucicchio C, Goette A, Geller C. Characterization of left ventricular activation in patients with heart failure and left bundle-branch block. Circulation 2004;109:1133-9.
31. Adelstein EC, Saba S. Usefulness of baseline electrocardiographic QRS complex pattern to predictor response to cardiac resynchronization. Am J Cardiol 2009; 103:238-42.